Gregory A Barme, MD
Urology · Berkeley
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
- Since medical school
- 29 years
- University of California, San Diego School of Medicine, 1997
On the public record
- California licence: Probation - Licensee Placed on Probation
- 1 Medical Board action on record
Offices
3 locations · Golden Gate Urology Inc · Genesis Healthcare Partners PC
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barme’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A79030 · Current
Licensed to practise in California · since 2002 · expires 2028-05-31 · University of California, San Diego School of Medicine. Board flags: Probation - Licensee Placed on Probation, Limitations on Practice.
Public record actions
| 2024-12-18 | Board disciplineDiscipline | Five years' probation with various terms and conditions. restrictions: shall not order, prescribe, dispense, administer, furnish, or possess any controlled substances, except those drugs listed in schedules iii, iv and v; shall not issue an oral or written recommendation or approval to a patient or patient's caregiver for the possession or cultivation of marijuana for personal medical purposes; and prohibited from supervising physician assistants and advanced practice nurses. · 8002023095237 |
Respondent made no admissions but was charged with having a condition affecting his ability to practice medicine safely; using drugs and/or alcohol in a manner as to be dangerous or injurious to himself, another person, or to the public; prescribing without an appropriate prior medical examination or indication; and unprofessional conduct. Acceptance of this stipulated settlement is not an admission of guilt. Effective 12/18/2024, revoked, stayed, placed on five years' probation until anticipated end date of 12/17/2029. Terms and conditions include, but are not limited to, prohibited from ordering, prescribing, dispensing, administering, furnishing, or possessing any controlled substances except for those listed in Schedules III, IV and V, and from issuing an oral or written recommendation or approval to possess or cultivate marijuana; maintaining a record of all controlled substances ordered, prescribed, dispensed, administered, or possessed and any recommendations or approvals to possess or cultivate marijuana; abstaining from the use of controlled substances; abstaining from the use of alcohol; completing a prescribing practices course and an ethics course; attending psychotherapy; obtaining a practice monitor; submitting to a psychiatric/substance abuse evaluation; notification of employer; submitting to biological fluid testing; attending substance abuse support group meetings; obtaining a worksite monitor; submitting proof of notification of Decision and Accusation to required parties; prohibited from supervising physician assistants and advanced practice nurses; reimbursing the Board its costs of investigation and enforcement in the amount of $13,790.00; submitting quarterly declarations of compliance with all conditions of probation; complying with the Board's probation unit; prohibited from engaging in the practice of medicine in Respondent's or patient's place of residence, unless the patient resides in a skilled nursing facility or other similar licensed facility; and paying costs associated with probation monitoring.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$274,970
Medicare paid this office $274,970 for 643 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 426 | $77,641 | $112 |
| Short return visit (20+ min) | 281 | $38,050 | $78 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $16,869 | None |
| New patient visit (45+ min) | 122 | $16,130 | $132 |
| Diagnostic exam of bladder and urethra using an endoscope | 56 | $15,110 | $236 |
See all 25 services
| Return visit (30+ min) | 426 | $77,641 | $112 |
| Short return visit (20+ min) | 281 | $38,050 | $78 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $16,869 | None |
| New patient visit (45+ min) | 122 | $16,130 | $132 |
| Diagnostic exam of bladder and urethra using an endoscope | 56 | $15,110 | $236 |
| Simple bladder irrigation and/or instillation | 53 | $5,028 | $71 |
| Simple change of bladder tube | 17 | $4,629 | $91 |
| Complicated insertion of bladder tube | 19 | $4,612 | $149 |
| Long return visit (40+ min) | 23 | $4,055 | $169 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $3,849 | $321 |
| Manual urinalysis test with examination using microscope, non-automated | 493 | $3,840 | $4 |
| Ultrasound scan of pelvic region through rectum | 19 | $2,867 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $2,721 | $105 |
| New patient visit (60+ min) | 12 | $2,168 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,160 | $70 |
| Electronic assessment of bladder emptying | 102 | $1,844 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 92 | $1,661 | $12 |
| Biopsy of prostate gland | 14 | $1,581 | $113 |
| Limited ultrasound scan of pelvis | 28 | $1,390 | $48 |
| Simple insertion of temporary bladder tube | 18 | $1,202 | $60 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,147 | $36 |
| Short return visit | 11 | $528 | $48 |
| Injection of drug or substance under skin or into muscle | 16 | $425 | $14 |
| Ultrasound scan of pelvic region through rectum | 13 | $376 | $29 |
| Ultrasonic guidance for needle placement | 13 | $341 | $26 |
Procedures Medicare counted
| Prostate resection | 17 | More than 74% of doctors who do this |
| Removal of tissue | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 131 | 163 | 134 | 128 | 24 | 140 |
| Electronic assessment of bladder emptying | 50 | 37 | 270 | 158 | 24 | 151 |
| Simple change of bladder tube | 56 | 80 | 109 | 58 | 12 | 51 |
| Diagnostic exam of bladder and urethra using an endoscope | 64 | 45 | 74 | 83 | 17 | 64 |
| Simple insertion of temporary bladder tube | 61 | 97 | 55 | 28 | – | 20 |
| Simple bladder irrigation and/or instillation | – | – | 39 | 60 | 17 | 71 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
643 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 15% · Women 15% · Also on Medicaid 21% · Health risk score 1.29. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 69% · Chronic kidney disease 29% · Cancer 26% · Diabetes 25% · Coronary heart disease 21% · Atrial fibrillation 20% · Depression 18% · Heart failure 14% · COPD 9% · Stroke 9% · Dementia 8%.
The office billed $824,724, Medicare allowed $364,270 and paid $274,970; for 5,298 services of 79 kinds; $43,361 of it was for drugs given in the office and $231,609 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 643 | 5,298 | 76 | 1.29 | $824,724 | $274,970 |
| 2023 | 269 | 1,106 | 76 | 1.18 | $155,976 | $47,806 |
| 2022 | 756 | 11,637 | 77 | 1.08 | $1,263,653 | $484,866 |
| 2021 | 777 | 14,961 | 76 | 1.22 | $1,641,558 | $620,246 |
| 2020 | 545 | 12,666 | 75 | 1.49 | $1,113,547 | $420,023 |
| 2019 | 551 | 8,678 | 75 | 1.49 | $839,286 | $302,945 |
| 2018 | 1,055 | 59,650 | 77 | 1.29 | $993,971 | $348,731 |
| 2017 | 1,045 | 57,347 | 77 | 1.22 | $902,156 | $321,572 |
| 2016 | 1,004 | 60,389 | 76 | 1.25 | $1,236,438 | $464,576 |
| 2015 | 1,086 | 71,283 | 76 | 1.21 | $1,556,647 | $543,771 |
| 2014 | 1,069 | 6,871 | 76 | 1.13 | $1,481,384 | $488,071 |
| 2013 | 1,115 | 7,662 | 76 | 1.18 | $1,341,772 | $465,180 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 151 | $15,003 | $90 |
| Short return visit (20+ min) | 86 | $7,356 | $66 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $3,585 | $211 |
| New patient visit (45+ min) | 22 | $2,775 | $126 |
| Simple bladder irrigation and/or instillation | 15 | $1,131 | $67 |
| Simple change of bladder tube | 11 | $985 | $82 |
| Manual urinalysis test with examination using microscope, non-automated | 186 | $855 | $4 |
| Electronic assessment of bladder emptying | 24 | $286 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 22 | $231 | $10 |
2022: 32 services
| Return visit (30+ min) | 514 | $87,853 | $105 |
| Detection test by nucleic acid for organism, amplified probe technique | 144 | $85,391 | $35 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 144 | $39,422 | $70 |
| Detection test for candida species (yeast), amplified probe technique | 144 | $32,843 | $35 |
| Short return visit (20+ min) | 265 | $31,779 | $78 |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $20,293 | $244 |
| New patient visit (45+ min) | 98 | $13,789 | $141 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $11,004 | None |
| Long return visit (40+ min) | 51 | $8,891 | $159 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 144 | $6,569 | $35 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 144 | $6,569 | $35 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 144 | $6,569 | $35 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 144 | $6,569 | $35 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 144 | $6,569 | $35 |
| Ultrasound scan of pelvic region through rectum | 40 | $5,969 | $146 |
| Simple change of bladder tube | 16 | $5,459 | $94 |
| Manual urinalysis test with examination using microscope, non-automated | 603 | $4,240 | $4 |
| Simple bladder irrigation and/or instillation | 44 | $4,126 | $69 |
| Biopsy of prostate gland | 17 | $3,548 | $209 |
| New patient visit (60+ min) | 19 | $3,514 | $185 |
| Short return visit | 49 | $3,064 | $52 |
| Limited ultrasound scan of pelvis | 52 | $2,943 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,072 | $90 |
| Electronic assessment of bladder emptying | 116 | $1,908 | $12 |
| Simple insertion of temporary bladder tube | 19 | $1,680 | $60 |
| Bcg live intravesical instillation, 1 mg | 11 | $1,677 | None |
| Instillation of anti-cancer drug into bladder | 13 | $1,629 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,438 | $63 |
| Ultrasound measurement of bladder capacity after voiding | 97 | $1,334 | $10 |
| Ultrasonic guidance for needle placement | 24 | $1,332 | $55 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $744 | $34 |
| Injection of drug or substance under skin or into muscle | 19 | $539 | $14 |
2021: 32 services
| Detection test by nucleic acid for organism, amplified probe technique | 163 | $112,674 | $35 |
| Return visit (30+ min) | 546 | $98,268 | $111 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 163 | $52,018 | $70 |
| Detection test for candida species (yeast), amplified probe technique | 163 | $43,336 | $35 |
| Short return visit (20+ min) | 212 | $34,019 | $83 |
| Long return visit (40+ min) | 175 | $31,089 | $147 |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $17,941 | $242 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $14,549 | None |
| Simple change of bladder tube | 20 | $10,251 | $94 |
| New patient visit (60+ min) | 47 | $8,684 | $185 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 163 | $8,667 | $35 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 163 | $8,667 | $35 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 163 | $8,667 | $35 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 163 | $8,667 | $35 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 163 | $8,632 | $35 |
| Ultrasound scan of pelvic region through rectum | 34 | $6,203 | $148 |
| New patient visit (45+ min) | 44 | $5,950 | $135 |
| Manual urinalysis test with examination using microscope, non-automated | 613 | $4,539 | $4 |
| Complicated insertion of bladder tube | 21 | $4,262 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,555 | $94 |
| Simple insertion of temporary bladder tube | 23 | $3,471 | $63 |
| Electronic assessment of bladder emptying | 204 | $3,456 | $13 |
| Simple bladder irrigation and/or instillation | 31 | $3,027 | $78 |
| Biopsy of prostate gland | 13 | $1,526 | $117 |
| Ultrasound measurement of bladder capacity after voiding | 106 | $1,439 | $11 |
| Limited ultrasound scan of pelvis | 23 | $1,313 | $47 |
| Ultrasonic guidance for needle placement | 19 | $1,265 | $58 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,117 | $32 |
| Short return visit | 15 | $881 | $55 |
| Injection of drug or substance under skin or into muscle | 19 | $642 | $14 |
| Ultrasound scan of pelvic region through rectum | 16 | $485 | $30 |
| Ultrasonic guidance for needle placement | 16 | $449 | $28 |
2020: 30 services
| Detection test by nucleic acid for organism, amplified probe technique | 149 | $100,677 | $35 |
| Return visit (30+ min) | 349 | $52,702 | $88 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 149 | $30,986 | $70 |
| Short return visit (20+ min) | 213 | $26,600 | $64 |
| Detection test for candida species (yeast), amplified probe technique | 149 | $15,489 | $35 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $9,403 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $9,290 | $206 |
| New patient visit (45+ min) | 72 | $8,252 | $115 |
| Detection test by nucleic acid for cytomegalovirus (cmv), amplified probe technique | 149 | $7,744 | $35 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 149 | $7,744 | $35 |
| Detection test by nucleic acid for herpes simplex virus, amplified probe technique | 149 | $7,744 | $35 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 149 | $7,744 | $35 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 149 | $7,744 | $35 |
| Simple change of bladder tube | 17 | $7,108 | $89 |
| Long return visit (40+ min) | 40 | $6,046 | $129 |
| Simple insertion of temporary bladder tube | 31 | $5,743 | $59 |
| Complicated insertion of bladder tube | 26 | $4,413 | $134 |
| Ultrasound scan of pelvic region through rectum | 23 | $4,059 | $145 |
| New patient visit (60+ min) | 18 | $3,324 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,927 | $183 |
| Manual urinalysis test with examination using microscope, non-automated | 394 | $2,734 | $4 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,202 | $65 |
| Ultrasound measurement of bladder capacity after voiding | 107 | $1,638 | $10 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,076 | $72 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution | 85 | $928 | $9 |
| Ultrasonic guidance for needle placement | 13 | $783 | $56 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $561 | $31 |
| Short return visit | 12 | $439 | $37 |
| Electronic assessment of bladder emptying | 34 | $417 | $11 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $187 | $16 |
2019: 31 services
| Return visit (30+ min) | 337 | $51,231 | $89 |
| Detection test by nucleic acid for organism, amplified probe technique | 54 | $45,699 | $38 |
| Short return visit (20+ min) | 229 | $29,397 | $65 |
| New patient visit (45+ min) | 100 | $12,411 | $124 |
| Diagnostic exam of bladder and urethra using an endoscope | 52 | $11,414 | $178 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 41 | $10,394 | $76 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $9,298 | None |
| Long return visit (40+ min) | 47 | $7,652 | $130 |
| Detection test for candida species (yeast), amplified probe technique | 51 | $6,266 | $38 |
| Complicated insertion of bladder tube | 20 | $5,082 | $127 |
| Simple change of bladder tube | 12 | $4,937 | $88 |
| Biopsy of prostate gland | 19 | $4,598 | $242 |
| Manual urinalysis test with examination using microscope, non-automated | 466 | $4,177 | $4 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,938 | $179 |
| Detection test by nucleic acid for cytomegalovirus (cmv), amplified probe technique | 54 | $3,515 | $38 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 54 | $3,515 | $38 |
| Detection test by nucleic acid for herpes simplex virus, amplified probe technique | 54 | $3,515 | $38 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 54 | $3,515 | $38 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 54 | $3,515 | $38 |
| Simple insertion of temporary bladder tube | 22 | $3,499 | $57 |
| Ultrasound scan of pelvic region through rectum | 25 | $3,302 | $127 |
| New patient visit (60+ min) | 18 | $2,919 | $162 |
| Short return visit | 53 | $2,847 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,738 | $64 |
| Ultrasound measurement of bladder capacity after voiding | 84 | $1,653 | $13 |
| Ultrasonic guidance for needle placement | 22 | $1,254 | $55 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $1,103 | $28 |
| Complicated insertion of bladder tube | 11 | $966 | $69 |
| Electronic assessment of bladder emptying | 37 | $661 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $606 | $22 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution | 40 | $518 | $9 |
2018: 28 services
| Return visit (30+ min) | 817 | $93,960 | $80 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 44 | $32,334 | None |
| Short return visit (20+ min) | 328 | $30,282 | $58 |
| Diagnostic exam of bladder and urethra using an endoscope | 124 | $21,334 | $137 |
| New patient visit (45+ min) | 122 | $14,436 | $118 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 87 | $12,786 | $137 |
| Long return visit (40+ min) | 85 | $10,905 | $114 |
| Biopsy of prostate gland | 34 | $6,637 | $195 |
| Complicated insertion of bladder tube | 35 | $6,118 | $107 |
| New patient visit (60+ min) | 39 | $6,071 | $156 |
| Manual urinalysis test with examination using microscope, automated | 844 | $5,839 | $4 |
| Ultrasound scan of pelvic region through rectum | 47 | $4,485 | $86 |
| Complete ultrasound scan behind abdominal cavity | 41 | $4,361 | $99 |
| Injection of drug or substance under skin or into muscle | 57 | $3,919 | $16 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,152 | $109 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $2,874 | $221 |
| Simple insertion of temporary bladder tube | 11 | $2,731 | $54 |
| Extended office or other outpatient service, first hour | 23 | $2,711 | $108 |
| Ultrasound measurement of bladder capacity after voiding | 131 | $2,511 | $14 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,336 | $212 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 76 | $2,077 | $16 |
| Complete ultrasound scan of pelvis | 19 | $1,822 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,564 | $60 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $1,268 | $25 |
| Injection, testosterone cypionate, 1 mg | 24 | $923 | None |
| Short return visit | 22 | $832 | $36 |
| Manual urinalysis test with examination using microscope, non-automated | 79 | $335 | $4 |
| Infusion, normal saline solution , 1000 cc | 117 | $267 | None |
2017: 28 services
| Return visit (30+ min) | 800 | $104,301 | $86 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 33 | $28,242 | None |
| Short return visit (20+ min) | 240 | $20,270 | $59 |
| Diagnostic exam of bladder and urethra using an endoscope | 111 | $18,578 | $139 |
| New patient visit (45+ min) | 143 | $18,523 | $130 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $11,505 | $719 |
| Complicated insertion of bladder tube | 28 | $7,941 | $109 |
| Long return visit (40+ min) | 58 | $7,666 | $116 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 45 | $6,719 | $140 |
| Manual urinalysis test with examination using microscope, automated | 870 | $6,454 | $4 |
| Injection of drug or substance under skin or into muscle | 36 | $4,783 | $21 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $4,724 | $363 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $4,516 | $251 |
| New patient visit (60+ min) | 25 | $4,480 | $179 |
| Biopsy of prostate gland | 22 | $3,980 | $181 |
| Ultrasound scan of pelvic region through rectum | 42 | $3,541 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 120 | $3,459 | $17 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $3,273 | $218 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,142 | $59 |
| Complete ultrasound scan behind abdominal cavity | 22 | $2,511 | $105 |
| Extended office or other outpatient service, first hour | 20 | $2,336 | $111 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,865 | $117 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 82 | $1,800 | $17 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 35 | $1,659 | $29 |
| Ultrasonic guidance for needle placement | 21 | $1,138 | $54 |
| Injection, testosterone cypionate, 1 mg | 28 | $896 | None |
| Infusion, normal saline solution , 1000 cc | 111 | $213 | None |
| Manual urinalysis test with examination using microscope, non-automated | 16 | $68 | $4 |
2016: 37 services
| Return visit (30+ min) | 835 | $122,968 | $85 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $34,169 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 109 | $23,910 | $172 |
| Cell examination of urine, manual | 35 | $21,369 | $578 |
| Short return visit (20+ min) | 192 | $18,076 | $62 |
| New patient visit (45+ min) | 120 | $15,073 | $126 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 20 | $13,955 | $157 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $8,068 | $733 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 46 | $7,143 | $152 |
| Mri scan of pelvis before and after contrast | 15 | $6,700 | $447 |
| Manual urinalysis test with examination using microscope, non-automated | 771 | $5,859 | $4 |
| Long return visit (40+ min) | 43 | $5,823 | $127 |
| Biopsy of prostate gland | 28 | $5,045 | $180 |
| New patient visit (60+ min) | 29 | $4,665 | $161 |
| Complicated insertion of bladder tube | 23 | $4,644 | $111 |
| Ultrasound measurement of bladder capacity after voiding | 133 | $4,427 | $17 |
| Injection of drug or substance under skin or into muscle | 48 | $4,368 | $21 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,963 | $360 |
| Simple insertion of temporary bladder tube | 17 | $3,267 | $63 |
| Ultrasound scan of pelvic region through rectum | 35 | $3,124 | $87 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,050 | $218 |
| Cell examination of specimen, selective cellular enhancement technique | 40 | $2,684 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,495 | $61 |
| Complete ultrasound scan behind abdominal cavity | 22 | $2,417 | $101 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $1,910 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,901 | $173 |
| Ultrasonic guidance for needle placement | 26 | $1,480 | $55 |
| Complete ultrasound scan of pelvis | 15 | $1,377 | $92 |
| Extended office or other outpatient service, first hour | 15 | $1,289 | $86 |
| Injection, testosterone cypionate, 1 mg | 31 | $1,057 | None |
| Short return visit | 26 | $985 | $38 |
| Manual urinalysis test with examination using microscope, automated | 190 | $909 | $4 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $630 | $17 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $565 | $33 |
| Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 15 | $242 | $1 |
| Urinalysis, manual test | 13 | $44 | $3 |
| Infusion, normal saline solution , 1000 cc | 21 | $30 | None |
2015: 36 services
| Return visit (30+ min) | 875 | $132,191 | $87 |
| Cell examination of urine, manual | 85 | $49,724 | $559 |
| Diagnostic exam of bladder and urethra using an endoscope | 129 | $29,287 | $183 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 32 | $28,986 | None |
| Short return visit (20+ min) | 294 | $27,704 | $59 |
| New patient visit (45+ min) | 164 | $22,284 | $136 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 24 | $10,309 | $430 |
| Pathology examination of tissue using a microscope, intermediate complexity | 35 | $10,080 | $38 |
| Mri scan of pelvis before and after contrast | 18 | $8,959 | $472 |
| Long return visit (40+ min) | 64 | $8,423 | $126 |
| Manual urinalysis test with examination using microscope, non-automated | 957 | $8,066 | $4 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 43 | $6,737 | $153 |
| Biopsy of prostate gland | 33 | $6,330 | $192 |
| New patient visit (60+ min) | 30 | $5,076 | $169 |
| Ultrasound measurement of bladder capacity after voiding | 146 | $5,042 | $17 |
| Cell examination of specimen, selective cellular enhancement technique | 83 | $4,794 | $54 |
| Injection of drug or substance under skin or into muscle | 36 | $4,719 | $21 |
| Simple insertion of temporary bladder tube | 22 | $4,468 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $4,174 | $174 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $4,019 | $251 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $3,864 | $215 |
| Ultrasound scan of pelvic region through rectum | 40 | $3,455 | $86 |
| Complicated insertion of bladder tube | 22 | $2,923 | $117 |
| Insertion of stent in ureter using an endoscope | 18 | $2,880 | $125 |
| Complete ultrasound scan behind abdominal cavity | 20 | $2,413 | $105 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 85 | $1,996 | $16 |
| Ultrasonic guidance for needle placement | 33 | $1,789 | $54 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,595 | $33 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $1,552 | $29 |
| Injection, testosterone cypionate, 1 mg | 26 | $1,333 | None |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,264 | $84 |
| Extended office or other outpatient service, first hour | 12 | $1,032 | $86 |
| Complete ultrasound scan of pelvis | 12 | $1,007 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $930 | $62 |
| Short return visit | 24 | $902 | $36 |
| Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 18 | $478 | $2 |
2014: 37 services
| Return visit (30+ min) | 856 | $118,443 | $83 |
| Cell examination of urine, manual | 85 | $48,090 | $540 |
| Short return visit (20+ min) | 339 | $31,339 | $57 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 39 | $29,853 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $28,219 | $173 |
| New patient visit (45+ min) | 117 | $14,986 | $128 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 28 | $11,625 | $415 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 43 | $11,598 | $252 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $9,970 | $712 |
| Shock wave crushing of kidney stones | 19 | $9,551 | $478 |
| Pathology examination of tissue using a microscope, intermediate complexity | 29 | $8,010 | $31 |
| Manual urinalysis test with examination using microscope, non-automated | 940 | $7,996 | $4 |
| New patient visit (60+ min) | 42 | $6,797 | $162 |
| Simple insertion of temporary bladder tube | 37 | $6,077 | $61 |
| Long return visit (40+ min) | 47 | $6,036 | $123 |
| Biopsy of prostate gland | 31 | $5,575 | $180 |
| Ultrasound measurement of bladder capacity after voiding | 151 | $4,856 | $17 |
| Cell examination of specimen, selective cellular enhancement technique | 84 | $4,585 | $52 |
| Insertion of stent in ureter using an endoscope | 18 | $4,103 | $132 |
| Injection of drug or substance under skin or into muscle | 48 | $4,093 | $20 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $3,714 | $206 |
| Complete ultrasound scan behind abdominal cavity | 29 | $3,534 | $110 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,391 | $242 |
| Ultrasound scan of pelvic region through rectum | 37 | $3,266 | $80 |
| Complicated insertion of bladder tube | 21 | $2,947 | $109 |
| Short return visit | 61 | $2,434 | $35 |
| Ultrasonic guidance for needle placement | 31 | $2,073 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 72 | $1,921 | $17 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,851 | $84 |
| Complete ultrasound scan of pelvis | 21 | $1,804 | $82 |
| New patient visit (30+ min) | 20 | $1,592 | $80 |
| Simple bladder irrigation and/or instillation | 11 | $1,486 | $71 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $949 | $28 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 21 | $753 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $684 | $33 |
| Injection, testosterone cypionate, up to 100 mg | 12 | $122 | None |
| Imaging guidance for procedure, 60 minutes or less | 11 | $92 | $7 |
2013: 35 services
| Return visit (30+ min) | 907 | $124,035 | $86 |
| Short return visit (20+ min) | 358 | $42,519 | $60 |
| Cell examination of urine, manual | 62 | $36,227 | $557 |
| Diagnostic exam of bladder and urethra using an endoscope | 143 | $30,246 | $177 |
| New patient visit (45+ min) | 207 | $27,702 | $134 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $19,485 | None |
| Pathology examination of tissue using a microscope, intermediate complexity | 28 | $13,006 | $57 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $9,874 | $705 |
| Manual urinalysis test with examination using microscope, non-automated | 1,021 | $9,634 | $4 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 39 | $9,129 | $217 |
| Ultrasound measurement of bladder capacity after voiding | 176 | $6,399 | $18 |
| Ultrasonic guidance for needle placement | 31 | $6,314 | $191 |
| Cell examination of specimen, selective cellular enhancement technique | 64 | $6,030 | $91 |
| Bcg (intravesical) per instillation | 12 | $5,430 | None |
| Instillation of anti-cancer drug into bladder | 13 | $5,384 | $91 |
| Biopsy of prostate gland | 29 | $5,257 | $175 |
| Insertion of stent in ureter using an endoscope | 23 | $4,715 | $118 |
| Simple insertion of temporary bladder tube | 35 | $4,546 | $64 |
| Injection of drug or substance under skin or into muscle | 58 | $4,453 | $22 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $3,948 | $219 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,833 | $213 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,753 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,346 | $167 |
| Ultrasound scan of pelvic region through rectum | 34 | $2,558 | $66 |
| Complicated insertion of bladder tube | 15 | $2,410 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,057 | $114 |
| New patient visit (60+ min) | 12 | $2,005 | $167 |
| Short return visit | 43 | $1,638 | $36 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 63 | $1,467 | $17 |
| Extended office or other outpatient service, first hour | 15 | $1,314 | $82 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $755 | $30 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 32 | $606 | None |
| Injection, testosterone cypionate, up to 100 mg | 24 | $347 | None |
| Urinalysis, manual test | 15 | $52 | $3 |
| Infusion, normal saline solution , 1000 cc | 29 | $24 | None |
Medicaid work
$771 in 2024
Medicaid paid $771 for 29 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 15 | $752 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 14 | $19 |
| 2024 | 29 | 2 | 15 | $771 |
Drugs they prescribed that Part D paid
$456,976
Pharmacies billed $456,976 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,266) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
1,102 generic and fewer than 11 brand-name prescriptions · $456,976 in drug cost · 274 antibiotic prescriptions to 158 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 19 | $278,763 | $14,672 |
| Myrbetriq | 68 | $59,606 | $877 |
| Gemtesa | 66 | $51,924 | $787 |
| Mirabegron Er | 12 | $7,358 | $613 |
| Tamsulosin | 280 | $5,229 | $19 |
See all 20 drugs
| Xtandi | 19 | $278,763 | $14,672 |
| Myrbetriq | 68 | $59,606 | $877 |
| Gemtesa | 66 | $51,924 | $787 |
| Mirabegron Er | 12 | $7,358 | $613 |
| Tamsulosin | 280 | $5,229 | $19 |
| Tadalafil | 81 | $4,638 | $57 |
| Silodosin | 26 | $2,418 | $93 |
| Testosterone | 31 | $2,408 | $78 |
| Alfuzosin Hcl Er | 87 | $1,942 | $22 |
| Finasteride | 106 | $1,675 | $16 |
| Nitrofurantoin | 30 | $1,439 | $48 |
| Cefdinir | 62 | $1,052 | $17 |
| Dutasteride | 38 | $922 | $24 |
| Testosterone Cypionate | 16 | $462 | $29 |
| Ciprofloxacin | 97 | $446 | $5 |
| Oxybutynin Chloride Er | 35 | $386 | $11 |
| Doxazosin Mesylate | 20 | $304 | $15 |
| Sulfamethoxazole-Trimethoprim | 41 | $281 | $7 |
| Bicalutamide | 16 | $218 | $14 |
| Terazosin | 12 | $154 | $13 |
Year by year
| 2024 | 1,266 | 382 | 0% (0) | None | $456,976 |
| 2023 | 837 | 319 | None | 10% | $262,821 |
| 2022 | 2,315 | 581 | 3% (58) | 10% | $283,545 |
| 2021 | 2,149 | 565 | 2% (41) | None | $302,328 |
| 2020 | 1,893 | 465 | 3% (47) | None | $397,569 |
| 2019 | 2,038 | 614 | 3% (55) | None | $438,781 |
| 2018 | 2,791 | 613 | 2% (51) | 19% | $342,435 |
| 2017 | 2,857 | 576 | 2% (48) | None | $426,975 |
| 2016 | 3,124 | 582 | 2% (46) | None | $312,025 |
| 2015 | 2,973 | 570 | 2% (50) | None | $236,791 |
| 2014 | 2,726 | 536 | 2% (46) | 25% | $205,460 |
| 2013 | 2,488 | 498 | 2% (49) | None | $192,029 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Erleada | 12 | $162,718 | $13,560 |
| Myrbetriq | 46 | $37,069 | $806 |
| Gemtesa | 15 | $16,376 | $1,092 |
| Tamsulosin | 272 | $6,783 | $25 |
| Silodosin | 28 | $4,092 | $146 |
| Tadalafil | 67 | $3,746 | $56 |
| Dutasteride | 37 | $2,031 | $55 |
| Alfuzosin Hcl Er | 66 | $1,997 | $30 |
| Finasteride | 91 | $1,615 | $18 |
| Nitrofurantoin | 18 | $785 | $44 |
| Oxybutynin Chloride Er | 18 | $654 | $36 |
| Terazosin | 14 | $441 | $32 |
| Ciprofloxacin | 26 | $269 | $10 |
| Cefdinir | 14 | $264 | $19 |
| Doxazosin Mesylate | 11 | $238 | $22 |
2022: 23 drugs
| Myrbetriq | 128 | $88,540 | $692 |
| Gemtesa | 25 | $16,932 | $677 |
| Tamsulosin | 586 | $12,872 | $22 |
| Tadalafil | 175 | $12,515 | $72 |
| Silodosin | 79 | $11,522 | $146 |
| Dutasteride | 81 | $7,535 | $93 |
| Alfuzosin Hcl Er | 172 | $5,108 | $30 |
| Finasteride | 246 | $4,704 | $19 |
| Testosterone | 21 | $4,463 | $213 |
| Trospium Chloride Er | 13 | $3,304 | $254 |
| Nitrofurantoin Mono-Macro | 55 | $3,051 | $55 |
| Oxybutynin Chloride Er | 54 | $2,818 | $52 |
| Nitrofurantoin | 30 | $2,079 | $69 |
| Darifenacin Er | 13 | $2,046 | $157 |
| Potassium Citrate Er | 12 | $1,615 | $135 |
| Cefdinir | 78 | $1,523 | $20 |
| Doxazosin Mesylate | 52 | $1,207 | $23 |
| Ciprofloxacin | 160 | $1,009 | $6 |
| Oxazepam | 11 | $888 | $81 |
| Terazosin | 26 | $842 | $32 |
| Hydrocodone-Acetaminophen | 56 | $667 | $12 |
| Cephalexin | 26 | $538 | $21 |
| Sulfamethoxazole-Trimethoprim | 38 | $187 | $5 |
2021: 25 drugs
| Myrbetriq | 146 | $96,876 | $664 |
| Tadalafil | 173 | $13,930 | $81 |
| Abiraterone Acetate | 12 | $11,387 | $949 |
| Tamsulosin | 520 | $9,447 | $18 |
| Dutasteride | 94 | $8,051 | $86 |
| Silodosin | 43 | $6,091 | $142 |
| Darifenacin Er | 29 | $5,620 | $194 |
| Finasteride | 213 | $4,837 | $23 |
| Nitrofurantoin Mono-Macro | 80 | $4,690 | $59 |
| Potassium Citrate Er | 14 | $4,529 | $324 |
| Alfuzosin Hcl Er | 115 | $3,624 | $32 |
| Testosterone | 11 | $2,445 | $222 |
| Oxybutynin Chloride Er | 68 | $2,243 | $33 |
| Nitrofurantoin | 22 | $1,920 | $87 |
| Doxazosin Mesylate | 53 | $1,603 | $30 |
| Oxazepam | 12 | $1,445 | $120 |
| Terazosin | 25 | $866 | $35 |
| Cephalexin | 27 | $815 | $30 |
| Cefdinir | 58 | $796 | $14 |
| Ciprofloxacin | 151 | $736 | $5 |
| Hydrocodone-Acetaminophen | 37 | $316 | $9 |
| Amoxicillin-Clavulanate Potass | 19 | $251 | $13 |
| Oxybutynin Chloride | 16 | $176 | $11 |
| Sulfamethoxazole-Trimethoprim | 23 | $76 | $3 |
| Levofloxacin | 11 | $54 | $5 |
2020: 24 drugs
| Myrbetriq | 139 | $75,472 | $543 |
| Tadalafil | 197 | $15,528 | $79 |
| Tamsulosin | 432 | $8,434 | $20 |
| Dutasteride | 90 | $8,128 | $90 |
| Testosterone | 15 | $8,094 | $540 |
| Silodosin | 25 | $4,793 | $192 |
| Darifenacin Er | 15 | $4,769 | $318 |
| Nitrofurantoin Mono-Macro | 83 | $4,413 | $53 |
| Finasteride | 164 | $3,545 | $22 |
| Alfuzosin Hcl Er | 77 | $2,557 | $33 |
| Cephalexin | 55 | $1,688 | $31 |
| Oxybutynin Chloride Er | 48 | $1,667 | $35 |
| Trospium Chloride | 13 | $1,564 | $120 |
| Oxazepam | 12 | $1,184 | $99 |
| Doxazosin Mesylate | 34 | $977 | $29 |
| Ciprofloxacin | 128 | $742 | $6 |
| Hydrocodone-Acetaminophen | 40 | $693 | $17 |
| Terazosin | 17 | $597 | $35 |
| Cefdinir | 36 | $582 | $16 |
| Nitrofurantoin | 12 | $521 | $43 |
| Fluconazole | 21 | $277 | $13 |
| Amoxicillin-Clavulanate Potass | 17 | $257 | $15 |
| Levofloxacin | 14 | $159 | $11 |
| Sulfamethoxazole-Trimethoprim | 25 | $136 | $5 |
2019: 27 drugs
| Xtandi | 15 | $185,504 | $12,367 |
| Myrbetriq | 76 | $52,325 | $688 |
| Tadalafil | 161 | $31,795 | $197 |
| Vesicare | 26 | $17,078 | $657 |
| Tamsulosin | 456 | $10,727 | $24 |
| Toviaz | 12 | $9,212 | $768 |
| Cialis | 19 | $8,678 | $457 |
| Silodosin | 26 | $7,616 | $293 |
| Finasteride | 252 | $6,238 | $25 |
| Dutasteride | 65 | $5,462 | $84 |
| Alfuzosin Hcl Er | 110 | $3,849 | $35 |
| Nitrofurantoin Mono-Macro | 75 | $3,191 | $43 |
| Darifenacin Er | 19 | $2,927 | $154 |
| Potassium Citrate Er | 13 | $2,530 | $195 |
| Oxybutynin Chloride Er | 47 | $2,413 | $51 |
| Trospium Chloride | 18 | $1,981 | $110 |
| Cefdinir | 62 | $1,801 | $29 |
| Solifenacin | 12 | $1,697 | $141 |
| Doxazosin Mesylate | 42 | $1,456 | $35 |
| Ciprofloxacin | 137 | $852 | $6 |
| Terazosin | 19 | $757 | $40 |
| Hydrocodone-Acetaminophen | 49 | $643 | $13 |
| Cephalexin | 47 | $616 | $13 |
| Sulfamethoxazole-Trimethoprim | 39 | $275 | $7 |
| Fluconazole | 13 | $267 | $21 |
| Levofloxacin | 12 | $221 | $18 |
| Prednisone | 15 | $154 | $10 |
2018: 32 drugs
| Myrbetriq | 129 | $80,169 | $621 |
| Cialis | 161 | $69,905 | $434 |
| Vesicare | 65 | $34,045 | $524 |
| Androgel | 27 | $23,057 | $854 |
| Tamsulosin | 674 | $17,776 | $26 |
| Rapaflo | 25 | $16,281 | $651 |
| Toviaz | 19 | $11,668 | $614 |
| Tadalafil | 32 | $11,422 | $357 |
| Alfuzosin Hcl Er | 279 | $9,894 | $35 |
| Finasteride | 369 | $8,617 | $23 |
| Testosterone | 17 | $7,644 | $450 |
| Dutasteride | 43 | $5,785 | $135 |
| Potassium Citrate Er | 13 | $5,551 | $427 |
| Dutasteride-Tamsulosin | 21 | $4,442 | $212 |
| Oxybutynin Chloride Er | 58 | $3,523 | $61 |
| Cefdinir | 91 | $3,114 | $34 |
| Nitrofurantoin Mono-Macro | 71 | $2,833 | $40 |
| Doxazosin Mesylate | 60 | $2,152 | $36 |
| Desmopressin Acetate | 16 | $1,869 | $117 |
| Trospium Chloride | 18 | $1,658 | $92 |
| Ciprofloxacin | 207 | $1,502 | $7 |
| Bethanechol Chloride | 16 | $1,312 | $82 |
| Bicalutamide | 19 | $992 | $52 |
| Hydrocodone-Acetaminophen | 50 | $766 | $15 |
| Testosterone Cypionate | 14 | $749 | $53 |
| Terazosin | 28 | $746 | $27 |
| Doxycycline Hyclate | 12 | $407 | $34 |
| Sulfamethoxazole-Trimethoprim | 50 | $331 | $7 |
| Cephalexin | 33 | $253 | $8 |
| Ampicillin Trihydrate | 16 | $249 | $16 |
| Levofloxacin | 15 | $117 | $8 |
| Cyclobenzaprine | 15 | $106 | $7 |
2017: 31 drugs
| Xtandi | 12 | $120,476 | $10,040 |
| Cialis | 194 | $68,899 | $355 |
| Myrbetriq | 96 | $56,494 | $588 |
| Androgel | 43 | $30,087 | $700 |
| Vesicare | 46 | $22,275 | $484 |
| Tamsulosin | 666 | $19,691 | $30 |
| Rapaflo | 46 | $15,410 | $335 |
| Potassium Citrate Er | 22 | $10,239 | $465 |
| Alfuzosin Hcl Er | 337 | $9,310 | $28 |
| Finasteride | 376 | $8,190 | $22 |
| Testosterone | 13 | $7,165 | $551 |
| Dutasteride-Tamsulosin | 23 | $4,735 | $206 |
| Nitrofurantoin Mono-Macro | 79 | $3,594 | $45 |
| Oxybutynin Chloride Er | 60 | $2,974 | $50 |
| Dutasteride | 36 | $2,190 | $61 |
| Cefdinir | 72 | $2,187 | $30 |
| Doxazosin Mesylate | 69 | $1,904 | $28 |
| Desmopressin Acetate | 19 | $1,815 | $96 |
| Bethanechol Chloride | 35 | $1,660 | $47 |
| Ciprofloxacin | 181 | $1,407 | $8 |
| Bicalutamide | 20 | $820 | $41 |
| Cefuroxime | 11 | $764 | $69 |
| Terazosin | 34 | $625 | $18 |
| Doxycycline Hyclate | 18 | $408 | $23 |
| Hydrocodone-Acetaminophen | 48 | $397 | $8 |
| Sulfamethoxazole-Trimethoprim | 45 | $273 | $6 |
| Cephalexin | 22 | $249 | $11 |
| Ampicillin Trihydrate | 33 | $235 | $7 |
| Fluconazole | 13 | $201 | $15 |
| Levofloxacin | 19 | $182 | $10 |
| Cyclobenzaprine | 12 | $18 | $1 |
2016: 34 drugs
| Myrbetriq | 99 | $50,717 | $512 |
| Cialis | 116 | $32,460 | $280 |
| Androgel | 36 | $26,727 | $742 |
| Tamsulosin | 706 | $20,408 | $29 |
| Vesicare | 33 | $17,845 | $541 |
| Rapaflo | 42 | $15,803 | $376 |
| Elmiron | 17 | $14,582 | $858 |
| Axiron | 18 | $12,350 | $686 |
| Alfuzosin Hcl Er | 420 | $9,666 | $23 |
| Finasteride | 378 | $6,467 | $17 |
| Nitrofurantoin Mono-Macro | 107 | $4,714 | $44 |
| Jalyn | 21 | $4,487 | $214 |
| Potassium Citrate Er | 12 | $4,228 | $352 |
| Dutasteride-Tamsulosin | 19 | $4,116 | $217 |
| Dutasteride | 45 | $3,424 | $76 |
| Doxazosin Mesylate | 85 | $3,414 | $40 |
| Oxybutynin Chloride Er | 54 | $3,316 | $61 |
| Cefdinir | 91 | $2,995 | $33 |
| Ciprofloxacin | 254 | $2,314 | $9 |
| Doxycycline Hyclate | 19 | $1,248 | $66 |
| Cefuroxime | 17 | $1,248 | $73 |
| Desmopressin Acetate | 12 | $1,087 | $91 |
| Bethanechol Chloride | 29 | $816 | $28 |
| Terazosin | 59 | $815 | $14 |
| Hydrocodone-Acetaminophen | 46 | $662 | $14 |
| Bicalutamide | 23 | $579 | $25 |
| Cephalexin | 34 | $490 | $14 |
| Levofloxacin | 35 | $455 | $13 |
| Trospium Chloride Er | 11 | $427 | $39 |
| Allopurinol | 22 | $364 | $17 |
| Sulfamethoxazole-Trimethoprim | 63 | $344 | $5 |
| Amoxicillin-Clavulanate Potass | 15 | $252 | $17 |
| Fluconazole | 12 | $195 | $16 |
| Ampicillin Trihydrate | 23 | $187 | $8 |
2015: 30 drugs
| Myrbetriq | 83 | $32,026 | $386 |
| Rapaflo | 95 | $23,755 | $250 |
| Tamsulosin | 592 | $19,754 | $33 |
| Vesicare | 48 | $18,541 | $386 |
| Androgel | 32 | $17,034 | $532 |
| Avodart | 69 | $15,608 | $226 |
| Axiron | 20 | $14,828 | $741 |
| Jalyn | 71 | $13,337 | $188 |
| Cialis | 44 | $11,923 | $271 |
| Alfuzosin Hcl Er | 416 | $8,236 | $20 |
| Finasteride | 326 | $4,444 | $14 |
| Nitrofurantoin Mono-Macro | 83 | $4,344 | $52 |
| Testosterone | 11 | $3,766 | $342 |
| Doxazosin Mesylate | 89 | $3,405 | $38 |
| Cefdinir | 91 | $3,114 | $34 |
| Oxybutynin Chloride Er | 45 | $2,653 | $59 |
| Ciprofloxacin | 247 | $1,716 | $7 |
| Bethanechol Chloride | 36 | $1,643 | $46 |
| Dutasteride | 11 | $1,474 | $134 |
| Desmopressin Acetate | 12 | $1,098 | $91 |
| Hydrocodone-Acetaminophen | 49 | $836 | $17 |
| Bicalutamide | 35 | $810 | $23 |
| Terazosin | 72 | $775 | $11 |
| Nitrofurantoin | 21 | $609 | $29 |
| Fluconazole | 12 | $337 | $28 |
| Sulfamethoxazole-Trimethoprim | 64 | $295 | $5 |
| Allopurinol | 16 | $274 | $17 |
| Cephalexin | 31 | $273 | $9 |
| Levofloxacin | 25 | $225 | $9 |
| Ampicillin Trihydrate | 22 | $140 | $6 |
2014: 29 drugs
| Avodart | 172 | $31,200 | $181 |
| Jalyn | 103 | $20,816 | $202 |
| Myrbetriq | 58 | $19,234 | $332 |
| Vesicare | 53 | $15,914 | $300 |
| Rapaflo | 86 | $14,720 | $171 |
| Tamsulosin | 512 | $13,052 | $25 |
| Alfuzosin Hcl Er | 346 | $8,863 | $26 |
| Androgel | 13 | $7,330 | $564 |
| Axiron | 18 | $7,296 | $405 |
| Cialis | 33 | $6,686 | $203 |
| Nitrofurantoin Mono-Macro | 97 | $5,717 | $59 |
| Enablex | 14 | $4,348 | $311 |
| Finasteride | 248 | $3,688 | $15 |
| Oxybutynin Chloride Er | 50 | $2,637 | $53 |
| Cefdinir | 73 | $2,451 | $34 |
| Desmopressin Acetate | 23 | $2,196 | $95 |
| Doxazosin Mesylate | 58 | $2,095 | $36 |
| Ciprofloxacin | 233 | $1,305 | $6 |
| Hydrocodone-Acetaminophen | 41 | $907 | $22 |
| Terazosin | 57 | $762 | $13 |
| Bicalutamide | 29 | $678 | $23 |
| Bethanechol Chloride | 15 | $418 | $28 |
| Nitrofurantoin | 16 | $368 | $23 |
| Sulfamethoxazole-Trimethoprim | 57 | $334 | $6 |
| Levofloxacin | 32 | $309 | $10 |
| Cephalexin | 34 | $253 | $7 |
| Allopurinol | 18 | $248 | $14 |
| Amox Tr-Potassium Clavulanate | 11 | $224 | $20 |
| Ampicillin Trihydrate | 19 | $109 | $6 |
2013: 36 drugs
| Avodart | 133 | $19,886 | $150 |
| Vesicare | 65 | $17,267 | $266 |
| Rapaflo | 83 | $16,811 | $203 |
| Myrbetriq | 54 | $16,603 | $307 |
| Tamsulosin | 557 | $16,330 | $29 |
| Jalyn | 81 | $12,665 | $156 |
| Alfuzosin | 266 | $10,774 | $41 |
| Uroxatral | 19 | $5,970 | $314 |
| Androgel | 13 | $5,429 | $418 |
| Toviaz | 20 | $4,407 | $220 |
| Desmopressin Acetate | 34 | $4,236 | $125 |
| Enablex | 11 | $4,044 | $368 |
| Testim | 11 | $3,694 | $336 |
| Nitrofurantoin Mono-Macro | 66 | $3,622 | $55 |
| Finasteride | 131 | $3,504 | $27 |
| Oxybutynin Chloride Er | 32 | $2,193 | $69 |
| Cefdinir | 48 | $2,084 | $43 |
| Viagra | 12 | $1,967 | $164 |
| Cialis | 11 | $1,628 | $148 |
| Proscar | 13 | $1,535 | $118 |
| Terazosin | 96 | $1,444 | $15 |
| Ciprofloxacin | 228 | $1,358 | $6 |
| Doxazosin Mesylate | 67 | $1,350 | $20 |
| Cardura Xl | 11 | $781 | $71 |
| Nitrofurantoin | 16 | $529 | $33 |
| Oxybutynin Chloride | 17 | $501 | $29 |
| Bicalutamide | 12 | $484 | $40 |
| Hydrocodone-Acetaminophen | 46 | $459 | $10 |
| Bethanechol Chloride | 11 | $448 | $41 |
| Amox Tr-Potassium Clavulanate | 18 | $372 | $21 |
| Sulfamethoxazole-Trimethoprim | 58 | $355 | $6 |
| Cefuroxime | 18 | $272 | $15 |
| Levofloxacin | 22 | $259 | $12 |
| Cephalexin | 29 | $217 | $7 |
| Allopurinol | 17 | $198 | $12 |
| Ampicillin Trihydrate | 21 | $114 | $5 |
Money from drug and device companies
$1,980 in 2025
| 2025 | 23 | 69 | None | $1,980 |
| 2024 | 16 | 39 | None | $900 |
| 2023 | 4 | 11 | None | $245 |
| 2022 | 18 | 49 | None | $1,200 |
| 2021 | 13 | 35 | $400 | $1,089 |
| 2020 | 11 | 33 | $1,200 | $1,868 |
| 2019 | 14 | 49 | $1,000 | $2,364 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Erleada | $275 | 7 payments
|
| Astellas Pharma US | Xtandi | $214 | 6 payments
|
| Sumitomo Pharma America | Gemtesa | $198 | 9 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $185 | 7 payments
|
| Verity Pharmaceuticals | Trelstar | $165 | 8 payments
|
| Sun Pharmaceutical Industries | None | $104 | 1 payment
|
See all 69 published payments
| AngioDynamics | Meals · 2025-12-31 | Nanoknife | $46 |
| Janssen Biotech | Meals · 2025-12-30 | Erleada | $48 |
| Ambu | Meals · 2025-12-28 | None | $21 |
| Astellas Pharma US | Education · 2025-12-19 | None | $90 |
| Verity Pharmaceuticals | Meals · 2025-12-17 | Trelstar | $20 |
| Sumitomo Pharma America | Meals · 2025-12-12 | Gemtesa | $28 |
| Astellas Pharma US | Meals · 2025-12-11 | Xtandi | $31 |
| Progenics Pharmaceuticals | Meals · 2025-12-05 | Pylarify | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-02 | Nubeqa | $28 |
| Verity Pharmaceuticals | Meals · 2025-11-19 | Trelstar | $17 |
| ABC Home Medical Supply | Meals · 2025-11-18 | None | $33 |
| Sumitomo Pharma America | Meals · 2025-11-14 | Gemtesa | $20 |
| Janssen Biotech | Meals · 2025-11-12 | Erleada | $55 |
| Abbvie | Meals · 2025-11-11 | Lupron Depot | $17 |
| Ferring Pharmaceuticals | Meals · 2025-11-05 | Adstiladrin | $26 |
| Sumitomo Pharma America | Meals · 2025-10-31 | Gemtesa | $24 |
| Bluewind Medical | Meals · 2025-10-30 | Revi | $28 |
| ABC Home Medical Supply | Meals · 2025-10-24 | None | $26 |
| Verity Pharmaceuticals | Meals · 2025-10-22 | Trelstar | $15 |
| Astellas Pharma US | Meals · 2025-10-10 | Xtandi | $17 |
| Abbvie | Meals · 2025-10-06 | Lupron Depot | $21 |
| Janssen Biotech | Meals · 2025-10-01 | Erleada | $35 |
| Pfizer | Meals · 2025-09-22 | Xtandi | $19 |
| Boston Scientific | Meals · 2025-09-18 | Lithovue | $21 |
| Verity Pharmaceuticals | Meals · 2025-09-15 | Trelstar | $28 |
| Sumitomo Pharma America | Meals · 2025-09-12 | Gemtesa | $24 |
| Progenics Pharmaceuticals | Meals · 2025-09-09 | Pylarify | $19 |
| Astellas Pharma US | Meals · 2025-09-04 | Xtandi | $23 |
| ABC Home Medical Supply | Meals · 2025-08-28 | None | $19 |
| Accord Healthcare | Meals · 2025-08-27 | Camcevi | $14 |
| Verity Pharmaceuticals | Meals · 2025-08-20 | Trelstar | $22 |
| Astellas Pharma US | Meals · 2025-08-13 | Xtandi | $29 |
| Ferring Pharmaceuticals | Meals · 2025-08-12 | Adstiladrin | $21 |
| Janssen Biotech | Meals · 2025-08-06 | Erleada | $35 |
| Ferring Pharmaceuticals | Meals · 2025-08-01 | Adstiladrin | $26 |
| Teleflex | Meals · 2025-07-31 | Urolift | $45 |
| Sumitomo Pharma America | Meals · 2025-07-30 | Gemtesa | $25 |
| Urogen Pharma | Meals · 2025-07-29 | None | $23 |
| Verity Pharmaceuticals | Meals · 2025-07-28 | Trelstar | $16 |
| Accord Healthcare | Meals · 2025-07-21 | Camcevi | $88 |
| Pfizer | Meals · 2025-07-16 | Xtandi | $20 |
| Coloplast | Meals · 2025-07-08 | Titan | $48 |
| Endo USA | Meals · 2025-07-06 | Xiaflex | $29 |
| Janssen Biotech | Meals · 2025-07-02 | Erleada | $39 |
| Endo USA | Meals · 2025-06-25 | Xiaflex | $28 |
| Ferring Pharmaceuticals | Meals · 2025-06-25 | Adstiladrin | $24 |
| Verity Pharmaceuticals | Meals · 2025-06-24 | Trelstar | $28 |
| Sumitomo Pharma America | Meals · 2025-06-23 | Gemtesa | $23 |
| Progenics Pharmaceuticals | Meals · 2025-06-04 | Pylarify | $23 |
| Profound Medical | Meals · 2025-05-28 | Tulsa-Pro | $29 |
| Ferring Pharmaceuticals | Meals · 2025-05-27 | Adstiladrin | $29 |
| Verity Pharmaceuticals | Meals · 2025-05-13 | Tlando | $18 |
| Abbvie | Meals · 2025-05-12 | Lupron Depot | $15 |
| Janssen Biotech | Meals · 2025-05-09 | Erleada | $31 |
| Telix Pharmaceuticals | Meals · 2025-05-01 | Illuccix | $20 |
| Profound Medical | Meals · 2025-04-08 | Tulsa-Pro | $18 |
| Janssen Biotech | Meals · 2025-03-19 | Erleada | $33 |
| Ferring Pharmaceuticals | Meals · 2025-03-12 | Adstiladrin | $27 |
| Bluewind Medical | Meals · 2025-03-03 | Revi | $28 |
| Sun Pharmaceutical Industries | Meals · 2025-02-22 | None | $104 |
| Astellas Pharma US | Meals · 2025-02-18 | Xtandi | $25 |
| Abbvie | Meals · 2025-02-14 | Botox | $21 |
| Pfizer | Meals · 2025-02-12 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-02-04 | Gemtesa | $30 |
| Ferring Pharmaceuticals | Meals · 2025-01-31 | Adstiladrin | $33 |
| KARL STORZ Endoscopy-America | Meals · 2025-01-21 | N.A. | $18 |
| Urogen Pharma | Meals · 2025-01-15 | Jelmyto | $28 |
| Sumitomo Pharma America | Meals · 2025-01-08 | Orgovyx | $23 |
| Sumitomo Pharma America | Meals · 2025-01-08 | Orgovyx | $2 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $900
| Sumitomo Pharma America | Gemtesa | $214 | 10 payments
|
| Abbvie | Lupron Depot | $178 | 8 payments
|
| Janssen Biotech | Erleada | $70 | 2 payments
|
| Astellas Pharma US | Xtandi | $69 | 3 payments
|
| Pfizer | Xtandi | $62 | 4 payments
|
| Verity Pharmaceuticals | Trelstar | $40 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $34 | 1 payment
|
| Immunitybio | Anktiva | $32 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $29 | 1 payment
|
| Bluewind Medical | Revi | $27 | 1 payment
|
| Photocure | Cysview | $27 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $27 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $26 | 1 payment
|
| Urogen Pharma | Jelmyto | $25 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam System | $21 | 1 payment
|
| Boston Scientific | Greenlight Xps | $17 | 1 payment
|
2023: $245
| Astellas Pharma US | Xtandi | $146 | 7 payments
|
| Sumitomo Pharma America | Gemtesa | $57 | 2 payments
|
| Tolmar | Jatenzo | $29 | 1 payment
|
| AbbVie | Lupron Depot | $14 | 1 payment
|
2022: $1,200
| Astellas Pharma US | Myrbetriq | $377 | 17 payments
|
| Myovant Sciences | Orgovyx | $99 | 4 payments
|
| Conmed | Airseal | $80 | 1 payment
|
| Janssen Biotech | Erleada | $76 | 3 payments
|
| Abbvie | Lupron Depot | $76 | 3 payments
|
| Urovant Sciences | Gemtesa | $62 | 3 payments
|
| Amgen | Xgeva | $61 | 2 payments
|
| Accord Healthcare | Camcevi | $59 | 3 payments
|
| Blue Earth Diagnostics | Axumin | $58 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $46 | 2 payments
|
| UroGen Pharma | Jelmyto | $32 | 1 payment
|
| Olympus America | Itind System | $29 | 1 payment
|
| Boston Scientific | Rezum Generator | $29 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $28 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $27 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $25 | 1 payment
|
| Coloplast | Titan | $19 | 1 payment
|
| Pfizer | Xtandi | $18 | 1 payment
|
2021: $1,089
| Micro-tech Endoscopy USA | All Products | $400 | 1 payment
|
| Janssen Biotech | Erleada | $162 | 7 payments
|
| Astellas Pharma US | Myrbetriq | $139 | 9 payments
|
| Amgen | Xgeva | $86 | 3 payments
|
| AbbVie | Lupron Depot | $75 | 3 payments
|
| Myovant Sciences | Orgovyx | $42 | 2 payments
|
| Blue Earth Diagnostics | Axumin | $41 | 2 payments
|
| Urovant Sciences | Gemtesa | $39 | 2 payments
|
| Allergan | Botox | $32 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $23 | 1 payment
|
| Pfizer | Xtandi | $20 | 1 payment
|
| Acerus Pharmaceuticals | Natesto | $15 | 1 payment
|
| Coloplast | Titan | $15 | 1 payment
|
2020: $1,868
| Micro-tech Endoscopy USA | None | $1,200 | 2 payments
|
| NeoTract | Urolift | $264 | 9 payments
|
| Astellas Pharma US | Myrbetriq | $88 | 5 payments
|
| AbbVie | Lupron Depot | $72 | 4 payments
|
| Endo Pharmaceuticals | Xiaflex | $69 | 4 payments
|
| Janssen Biotech | Erleada | $48 | 2 payments
|
| Pfizer | Xtandi | $37 | 2 payments
|
| Boston Scientific | Spaceoar | $36 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Laborie Medical Technologies | None | $19 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $14 | 1 payment
|
2019: $2,364
| Micro-tech Endoscopy USA | All Products | $1,000 | 1 payment
|
| NeoTract | Urolift | $569 | 8 payments
|
| Dendreon Pharmaceuticals | Provenge | $121 | 6 payments
|
| Janssen Biotech | Zytiga | $121 | 7 payments
|
| Astellas Pharma US | Myrbetriq | $95 | 5 payments
|
| Endo Pharmaceuticals | Xiaflex | $90 | 5 payments
|
| AbbVie | Lupron Depot | $85 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $69 | 3 payments
|
| Amgen | Xgeva | $59 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $59 | 3 payments
|
| Blue Earth Diagnostics | Axumin | $34 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $24 | 1 payment
|
| Dentsply Ih | Lofric | $20 | 1 payment
|
| Pfizer | Xtandi | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1295700235
- Licence
- CA A79030California A79030: Current · expires 2028-05-31
- Trained
- University of California, San Diego School of Medicine, 1997 · 29 years ago
- Group
- Golden Gate Urology Inc · Genesis Healthcare Partners PC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2999 Regent St Ste 612, Berkeley, CA, 94705
- NPI first listed
- 2006-02-22
- NPI last updated
- 2023-07-20
- NPI record certified
- 2023-07-20
This is when the NPI record was last certified, not a medical board exam.